- The global RCM Market is projected to reach USD 67.8 billion by 2026 from USD 40.9 billion in 2021, at a CAGR of 10.6% during the forecast period.
According to the new market research report "Revenue Cycle Management/RCM Market by Product & Services (Eligibility Verification, Clinical Coding, CDI, Claims Processing, Denial Management, Outsourcing Services, Cloud), End User(Payers, Hospitals, Outpatient), Covid-19 Impact - Global Forecast to 2026", published by MarketsandMarkets™, the global RCM Market is projected to reach USD 67.8 billion by 2026 from USD 40.9 billion in 2021, at a CAGR of 10.6% during the forecast period.
Browse in-depth TOC on "Revenue Cycle Management Market"
242 – Tables40 – Figures286 – Pages
The growth of this market is majorly attributed to the need for increasing patient volumes, and the growing need to manage unstructured healthcare data. Also, growing regulatory requirements & government initiatives are expected to drive demand growth in the IoT medical devices market during the forecast period.
By product & services, segment the outsourcing services segment is expected to grow at the highest growth rate during the forecast period
Among the product & services, the outsourcing services segment is expected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the lack of IT infrastructure and the shortage of skilled HCIT personnel.
By delivery mode, the on-premise segment is expected to account for the largest share of the revenue cycle management market
The on-premise segment accounted for the largest share of the global RCM Market in 2020. The large share of this segment is attributed to the increasing demand for mobile support systems for better customer (patient) engagement platforms.
By end user, the healthcare providers segment is expected to account for the largest share of the RCM Market
Based on end user, the revenue cycle management market is segmented into healthcare providers and healthcare payers. Revenue cycle management solutions help healthcare providers automate the process from patient registration to billing and claims processing and provide better transparency that improves the overall financial health of the provider organization. This is a major factor driving the growth of this segment.
North America dominates the revenue cycle management market during the forecast period.
North America accounted for the largest share of the RCM Market in 2020. The large share of this region can be attributed to factors such as stringent regulations, increasing volume of claims denials, the presence of a high number of private healthcare payers and well-established government payers, and a large number of healthcare IT companies are some of the factors driving the growth of the revenue cycle management market in this region.
R1 RCM (US), Cerner Corporation (US), Optum (US) are the leading players in the market. Other players include McKesson Corporation (US), Change Healthcare (US), 3M (US), Experian plc (Ireland), Conifer Health Solutions (US), Allscripts Healthcare Solutions (US), GE Healthcare (US), Cognizant (US), athenahealth (US), SSI Group LLC (US), AdvantEdge Healthcare (US), and Huron Consulting Group (US)
Browse Related Reports:
Healthcare EDI Market by Component (Solution, Service), Delivery Mode (On-premise & Cloud, Mobile) Transaction Type (Claims Management, Payment Remittance, Payments, Healthcare Supply Chain), End-User - Global Forecast to 2025
Healthcare Interoperability Solutions Market by Type (EHR Interoperability, Health Information Exchange, Enterprise), Interoperability Levels (Foundational, Structural, Semantics), End User and Region - Global Forecast to 2024
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.